arrow
刘

刘盼盼 (Panpan Liu)

Sun Yat-sen University Cancer Center
H指数:35
被引数:3,858

个人简介

任职于中山大学,从事淋巴瘤及头颈肿瘤的内科治疗(包含免疫化疗、靶向治疗及CAR-T细胞疗法),具有丰富的临床经验;科学研究方向聚焦于基于临床重大问题的基础转化研究,从代谢角度深入研究肿瘤发生发展和耐药机制,探索肿瘤代谢特征与临床表型的内在联系和关键环节及靶向干预。以通讯作者或第一作者在Cell Death & Differentiation、Molecular Cancer、Redox Biology、Haematologica、Cancer Communications、STTT、Oncogene等杂志发表多篇高水平论文。主持国家自然科学基金青年及面上项目、广东省自然科学基金、广州市科技计划重点研发项目、中山大学青年教师培育项目等多项研究课题。

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial

泽鲁布替尼联合利妥昔单抗,随后进行缩短的化疗免疫疗法作为套细胞淋巴瘤的一线治疗方案(CHESS):一项II期试验

2026-03-280
OAAI
Anatomical laterality of primary intestinal diffuse large B-cell lymphoma independently stratifies survival: New prognostic nomogram incorporating tumor location

原发肠道弥漫大B细胞淋巴瘤的解剖学左右不对称性独立分层预后:纳入肿瘤位置的新型预后诺模图

2026-02-210
PRE
Genetics-nutrition interactions control diurnal enhancer-promoter dynamics and liver lipid metabolism

遗传-营养相互作用调控昼夜增强子-启动子动态和肝脏脂质代谢

2025-08-250
PRE
Cardiomyocyte-localized CCDC25 senses NET DNA to promote doxorubicin cardiotoxicity by activating autophagic flux

Nie, M.; Lei, D.; Liu, Z.; Zeng, K.; Liang, X.; Huang, P.; Wang, Y.; Sun, P.; Yang, H.; Liu, P.; et al. 心肌细胞定位的CCDC25通过感知NET DNA来促进多柔比星心脏毒性,其机制是激活自噬流。Nat. Cancer 2025, 6, 1400–1418. [Google Scholar] [CrossRef] [PubMed]

2025-05-290
PRE
Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study

在初诊早期不良及晚期经典霍奇金淋巴瘤患者中,PD1抗体联合AVD方案较ABVD方案疗效更优:一项回顾性匹配队列研究

2025-05-150
OA
Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial

尼妥珠单抗联合多西他赛和顺铂作为复发性或转移性鼻咽癌患者的一线治疗方案:一项多中心、II期临床试验

2025-05-060
OA
Chidamide, a Histone Deacetylase Inhibitor, Combined With R-GemOx in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (TRUST): A Multicenter, Single-Arm, Phase 2 Trial

Chidamide,一种组蛋白去乙酰化酶抑制剂,与R-GemOx联合用于复发/难治性弥漫大B细胞淋巴瘤(TRUST):一项多中心、单臂、II期临床试验

2025-05-020
OAAI